Quantcast

Latest Astellas Pharma Inc. Stories

2014-09-10 16:26:51

Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI(®) (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved...

2014-08-08 08:26:19

TOKYO, Aug. 8, 2014 /PRNewswire/ -- Cancer Research UK and its commercial arm, Cancer Research Technology ("CRT"), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, "Astellas") to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer. http://photos.prnewswire.com/prnvar/20140416/84970 As part of a new collaboration, Cancer Research UK, CRT and Astellas will conduct a two-year research programme in the UK to...

2014-06-11 08:30:30

Special Patient-Focused Event Kicks Off Astellas' Fifth Annual Changing Tomorrow Day Initiative KISSIMMEE, Fla., June 11, 2014 /PRNewswire/ -- About 1,400 Astellas Pharma employees will be descending on Give Kids The World (GKTW) for the second time to tackle projects ranging from landscaping to assembling furniture as well as resurfacing parking lots and roads. This year, Astellas is bringing an even bigger volunteer group than the record-breaking Astellas team that volunteered in...

2014-06-01 08:20:11

-Study appears in June 1 online edition- NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced the online publication in the New England Journal of Medicine of the results from the Phase 3 PREVAIL trial, an international, randomized, double-blind, placebo-controlled clinical study of enzalutamide. The study evaluated the benefit...

2014-05-27 12:32:32

LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Diabetic Nephropathy Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/diseases/global_diabetic_nephropathy_market_2014_2018.html About Diabetic NephropathyDiabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the...

2014-05-14 16:29:25

Eight abstracts will highlight enzalutamide studies in prostate and breast cancers NORTHBROOK, Ill. and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced that eight enzalutamide abstracts will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3 in Chicago. http://photos.prnewswire.com/prnvar/20140416/84970 The...

2014-05-06 08:33:30

TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy. This sNDA application was granted Priority Review...

2014-04-16 12:31:30

NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that it has reached an agreement with the U.S. Department of Justice to resolve civil claims regarding the marketing of MYCAMINE(®) (micafungin sodium) for injection. Under the agreement, Astellas will pay $7.3 million to the settling parties. The Department of Justice had investigated Astellas for alleged off-label...

2014-04-15 08:31:27

NEW YORK, April 15, 2014 /PRNewswire-USNewswire/ -- The National Kidney Foundation (NKF) announced today, during National Donate Life Month, that Astellas Pharma US, Inc. was named the first-ever National Presenting Sponsor for the Kidney Walk. Through this partnership, Astellas will support more than 85 Kidney Walk events being held in major cities across the country. "Our partnership with NKF exemplifies what Astellas and these walks are all about - enabling patients to be their own...

2014-04-03 08:28:53

TOKYO and SAN FRANCISCO, April 3, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Medivation Inc. (NASDAQ: MDVN) today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI(®) (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.